American Association for the Study of Liver Diseases

Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Thursday, November 9, 2023

As of September 30, 2023, the Company had cash, cash equivalents and marketable securities totaling $89.3 million.

Key Points: 
  • As of September 30, 2023, the Company had cash, cash equivalents and marketable securities totaling $89.3 million.
  • Research and development (R&D) expenses for the third quarter of 2023 were $16.5 million, compared to $20.7 million for the third quarter of 2022.
  • General and administrative (G&A) expenses for the third quarter of 2023 were $7.9 million, compared to $5.2 million for the third quarter of 2022.
  • Net loss for the third quarter of 2023 was $22.2 million, compared to $25.8 million for the third quarter of 2022, driven predominantly by a decrease in R&D expenses.

Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates

Retrieved on: 
Wednesday, November 8, 2023

Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyond

Key Points: 
  • Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyond
    SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today reported financial results for the third quarter ended September 30, 2023, and recent corporate updates.
  • We believe that the financial and scientific resources provided by the collaboration position us well to reach critical short- and long-term milestones and deliver value for patients and our shareholders.
  • Partnership includes Gilead opt-in rights on Assembly Bio’s current and future pipeline candidates, including two contributed Gilead herpesvirus programs.
  • Cash, cash equivalents and marketable securities were $46.2 million as of September 30, 2023, compared to $59.8 million as of June 30, 2023.

Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Retrieved on: 
Thursday, November 9, 2023

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that an abstract featuring preclinical data for its wholly owned PBGENE-HBV program has been accepted for late-breaker presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting being held in Boston, MA on November 10-14, 2023.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that an abstract featuring preclinical data for its wholly owned PBGENE-HBV program has been accepted for late-breaker presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting being held in Boston, MA on November 10-14, 2023.
  • Title: Preclinical efficacy and safety of ARCUS-POL nucleases for chronic hepatitis B: a potentially curative strategy
    Company-Hosted Webcast and Conference Call Information:
    Precision will host a conference call and webcast on Monday, November 13, 2023 at 4:30 PM ET to discuss PBGENE-HBV program updates.
  • The dial-in conference call number is (800) 715-9871 and the conference ID number for the call is 3866428.
  • Participants may access the live webcast, and accompanying presentation materials, as well as the archived webcast on Precision’s website in the Investors section under Events & Presentations: https://investor.precisionbiosciences.com/events-and-presentations .

Mallinckrodt to Present Breadth of Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Association for the Study of Liver Diseases (AASLD) 2023 Liver Meeting

Retrieved on: 
Wednesday, November 8, 2023

DUBLIN, Nov. 8, 2023 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, today announced the presentation of 11 scientific abstracts with findings from the latest clinical and health economics research with TERLIVAZ® (terlipressin) for injection for adult patients with hepatorenal syndrome (HRS) with rapid reduction in kidney function1 during the American Association for the Study of Liver Diseases (AASLD) 2023 Liver Meeting, taking place November 10-14, 2023 in Boston, MA.

Key Points: 
  • Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/9111651-mallinckrodt-aasld-2023-...
    Please see Limitation of Use and Important Safety Information, including Boxed Warning, below.
  • Data collected in retrospective, pooled, database, or post hoc analyses may have errors or omissions.
  • Outcomes may be influenced by therapies not evaluated in the study and the clinical/health economic outcomes may not be solely attributable to TERLIVAZ.
  • TERLIVAZ® is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.

Aligos Therapeutics to Present Multiple Posters at AASLD’s The Liver Meeting® 2023, Highlighting Progress for Its Clinical Stage Portfolio, including Lead THR-β Agonist for the Treatment of NASH, ALG-055009; ALG-000184, the Company’s Lead CAM-E Molecule,

Retrieved on: 
Tuesday, November 7, 2023

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that the company is presenting six posters at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2023, taking place in Boston, Massachusetts, November 10 – 14, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that the company is presenting six posters at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2023, taking place in Boston, Massachusetts, November 10 – 14, 2023.
  • The posters, which include both clinical and preclinical data on the nonalcoholic steatohepatitis (NASH) program, ALG-055009, currently in Phase 2-enabling studies, as well as preclinical and clinical data from the chronic hepatitis B (CHB) portfolio, will be available on the Aligos website in the Scientific Presentations & Conferences section following the conclusion of the conference.
  • Title: Safety, pharmacokinetics, and pharmacodynamics of multiple ascending oral doses of ALG-055009, a thyroid hormone receptor beta agonist, in hyperlipidaemic subjects and relative bioavailability/food effect of a solid formulation in healthy volunteers
    Title: Nonclinical efficacy, pharmacokinetic/pharmacodynamic (PK/PD), and toxicology profile of ALG-055009, a novel and potent thyroid hormone receptor β agonist, for the treatment of non-alcoholic steatohepatitis (NASH)
    Title: Preclinical resistance profile and antiviral activity of the best-in-class CAM-E ALG-001075, the parent compound of ALG-000184
    Title: Prolonged (>24 week) dosing with the oral CAM-E compound ALG-000184 results in multi-log reductions in hepatitis B surface antigen, HBV DNA, and HBV RNA levels in untreated E antigen positive subjects with chronic hepatitis B

Boston Pharmaceuticals To Present New Phase 2a Data From Investigational BOS-580 NASH Program at AASLD The Liver Meeting® 2023

Retrieved on: 
Tuesday, November 7, 2023

Boston Pharmaceuticals , a clinical-stage biopharmaceutical company developing differentiated molecules addressing serious liver diseases, today announced it will present new data supporting its long-acting dosing schedule and an analysis of treatment in diabetic sub-groups from the Phase 2a Part A clinical program evaluating BOS-580 for the treatment of non-alcoholic steatohepatitis (NASH), at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place November 10-14, 2023, in Boston.

Key Points: 
  • Boston Pharmaceuticals , a clinical-stage biopharmaceutical company developing differentiated molecules addressing serious liver diseases, today announced it will present new data supporting its long-acting dosing schedule and an analysis of treatment in diabetic sub-groups from the Phase 2a Part A clinical program evaluating BOS-580 for the treatment of non-alcoholic steatohepatitis (NASH), at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place November 10-14, 2023, in Boston.
  • BOS-580 is a long-acting, highly engineered fibroblast growth factor 21 (FGF21) analog administered via a once-monthly subcutaneous injection.
  • BOS-580 is designed to reduce liver fat content, liver inflammation as evidenced by biomarkers of liver injury and fibrosis and improve metabolism as evidenced by the impact on metabolic biomarkers in patients with NASH.
  • We are especially pleased that our presentation on the impact of BOS-580 treatment in subgroups of NASH patients who also have diabetes was designated as a poster of distinction by AASLD, placing it among the foremost presentations at this year’s meeting,” stated Sophie Kornowski, PharmD, CEO of Boston Pharmaceuticals.

Gilead Sciences Announces Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2023.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2023.
  • During the third quarter of 2023, Gilead generated $1.8 billion in operating cash flow.
  • During the third quarter of 2023, Gilead repaid $2.3 billion of debt, paid dividends of $953 million and repurchased $300 million of common stock.
  • Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are provided in the accompanying tables.

Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023  

Retrieved on: 
Monday, November 6, 2023

The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker.

Key Points: 
  • The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker.
  • Two additional scientific abstracts from the NATIVE Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH have been selected  for presentation.
  • The two abstracts show:
    the correlation between the increase of adiponectin under lanifibranor and the improvement of histological and serum markers of NASH severity both in terms of activity and fibrosis.
  • the improvement of liver histology and markers of cardiometabolic health in patients with NASH treated with lanifibranor, independent of PNPLA3 genotype.

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD

Retrieved on: 
Friday, November 3, 2023

NORCROSS, Ga., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will share five scientific presentations at The Liver Meeting™ 2023, hosted by the American Association for the Study of Liver Diseases (AASLD).

Key Points: 
  • NORCROSS, Ga., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will share five scientific presentations at The Liver Meeting™ 2023, hosted by the American Association for the Study of Liver Diseases (AASLD).
  • The Liver Meeting™ will be held November 10-14, 2023, in Boston, Mass.
  • “This year again we are happy to share some of the progress we have made in our global program with belapectin, our galectin-3 inhibitor.
  • We are also proud to bring additional knowledge to the field regarding liver cirrhosis, a disease that dramatically affects the lives of our patients and has been neglected for far too long,” said Pol Boudes, M.D., Chief Medical Officer of Galectin Therapeutics.

Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023

Retrieved on: 
Thursday, November 2, 2023

"We are very pleased to share with the scientific and clinical community supportive data for bemnifosbuvir and ruzasvir, highlighting the potential to use these two compounds together as a novel treatment for hepatitis C virus (HCV)," said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals.

Key Points: 
  • "We are very pleased to share with the scientific and clinical community supportive data for bemnifosbuvir and ruzasvir, highlighting the potential to use these two compounds together as a novel treatment for hepatitis C virus (HCV)," said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals.
  • "We are encouraged by the highly potent, pan-genotypic antiviral activity of these compounds, along with the favorable drug-drug interaction and safety profile observed to-date, which supports their use in combination.
  • Despite treatment options for HCV, there remains a large, underserved HCV patient population that continues to grow dramatically due to the opioid crisis, injection drug use and HCV reinfection."
  • Details for the presentations are as follows: